Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 25;60(3):385.
doi: 10.3390/medicina60030385.

Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review

Poramate Pitak-Arnnop  1   2 , Popchai Ngamskulrungroj  3 , Nithi Mahanonda  4 , Prim Auychai  5   6 , Benjamin Frech  2   7 , Veronika Shavlokhova  2   8 , Christian Stoll  2
Affiliations
Review

Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review

Poramate Pitak-Arnnop et al. Medicina (Kaunas). .

Abstract

While the World Health Organization (WHO) has de-escalated coronavirus disease 2019 (COVID-19) from a global health emergency, ongoing discussions persist as new viral variants. This article aimed to consolidate German recommendations and international research to offer health care providers (HCPs) a comprehensive guide on COVID-19 boosters in 2024. The review outlines key recommendations from the German Robert Koch Institute. HCPs should receive COVID-19 boosters at least 12 months after their last vaccination or COVID-19 infection, contingent on the prevalent viral variant(s) in the region. However, excessive doses and/or frequent boosters, especially with mRNA vaccines, may lead to immune imprinting, T-cell exhaustion, and immunoglobulin (Ig) switching. Notably, this review highlights the significance of Ig, particularly IgA and IgG subclasses, in influencing infection risk and disease progression. Furthermore, it explores the implications of mRNA vaccine technology and potential adverse effects related to excessive dosing. In conclusion, this article provides a comprehensive analysis of COVID-19 vaccine boosters for HCPs, synthesising current recommendations, scientific debates, and considerations for optimising protection against SARS-CoV-2 in the evolving landscape of the post-pandemic era.

Keywords: COVID-19; health care provider; review; vaccine booster.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest related to this study and had full freedom in conducting this investigation and preparing the manuscript.

References

    1. Wei D., Yu X., Li Y., Chen Y., Chen E., Wang Y., Yang Z., Zhang X. Sequential reinfection with Omicron variants elicits broader neutralizing antibody profiles in booster vaccinees and reduces the duration of viral shedding. J. Med. Virol. 2023;95:e29151. doi: 10.1002/jmv.29151. - DOI - PubMed
    1. Robert Koch Institut, COVID-19-Impfempfehlung (Stand 11.01.2024) [(accessed on 31 January 2024)]. Available online: https://www.rki.de/SharedDocs/FAQ/COVID-Impfen/FAQ_Liste_STIKO_Empfehlun....
    1. Jacobsen H., Sitaras I., Katzmarzyk M., Jiménez V.C., Naughton R., Higdon M.M., Knoll M.D. Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2. NPJ Vaccines. 2023;8:159. doi: 10.1038/s41541-023-00756-1. - DOI - PMC - PubMed
    1. Hornsby H., Nicols A.R., Longet S., Liu C., Tomic A., Angyal A., Kronsteiner B., Tyerman J.K., Tipton T., Zhang P., et al. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nat. Commun. 2023;14:5065. doi: 10.1038/s41467-023-40592-4. - DOI - PMC - PubMed
    1. Pérez-Alós L., Hansen C.B., Almagro Armenteros J.J., Madsen J.R., Heftdal L.D., Hasselbalch R.B., Pries-Heje M.M., Bayarri-Olmos R., Jarlhelt I., Hamm S.R., et al. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk. Nat. Commun. 2023;14:5624. doi: 10.1038/s41467-023-41342-2. - DOI - PMC - PubMed